The U.S. Food and Drug Administration (FDA) has approved oral vismodegib (Erivedge™) for the treatment of adult patients with locally advanced basal cell carcinoma who are not candidates for surgery or radiation and for those with metastatic disease. The drug initially was tested at Scottsdale Healthcare in Arizona.
References
Joensuu, H., Eriksson, M., Hatrmann, J., Sundby Hall, K., Schutte, J., Reichardt, A., … Reichardt, P. (2011). Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO) [Abstract LBA1]. Retrieved from
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78836
Novartis Pharmaceuticals. (2011). Gleevec® (imatinib mesylate) [Prescribing information]. East Hanover, NJ: Author.
Jagger, J., Perry, J., Parker, G., & Phillips, E. K. (2011). Nursing 2011 survey results: Blood exposure risk during peripheral IV catheter insertion and removal. Nursing, 41(12), 45-49. doi:10.1097/01.NURSE.0000407678.81635.62
Onia, R., Eshun-Wilson, I., Arce, C., Ellis, C., Parvu, V., Hassman, D., & Kassler-Taub, K. (2011). Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. Current Medical Research and Opinion, 27, 1339-1346. doi:10.1185/03007995.2011.581275